SCHEMBL5875847

SCHEMBL5875847

NCc1cnc(C(N)=O)s1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 2/20 0.36
LOX P28300 1/20 0.36
SMYD3 Q9H7B4 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
AURKA O14965 1/20 0.33
RPS6KB1 P23443 1/20 0.33
AURKB Q96GD4 1/20 0.33
TSHR P16473 2/20 0.33
ADORA3 P0DMS8 1/20 0.32
MC4R P32245 1/20 0.32
ADRA1A P35348 1/20 0.32
MC3R P41968 1/20 0.32
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32
APH1A Q96BI3 1/20 0.32
PSENEN Q9NZ42 1/20 0.32
PARP15 Q460N3 1/20 0.32
PARP10 Q53GL7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5875836 0.83 SMN1; SMN2 (0.34) SMYD3SMN1; SMN2TSHRADORA3MC4R
SCHEMBL2827606 0.82 SMYD3 (0.47) SMYD3SMN1; SMN2TSHRPARP10IKBKB
SCHEMBL7996248 0.82 SIRT6 (0.34) SMYD3SMN1; SMN2TSHRADORA3MC4R
SCHEMBL5875649 0.77 CYP2A6 (0.35) SMYD3SMN1; SMN2TSHRNNMTCYP2A6
SCHEMBL5875757 0.76 FDPS (0.48) SMYD3SMN1; SMN2TSHRIKBKB
SCHEMBL17525142 0.75 F2 (0.43) LOXL2LOXSMN1; SMN2PSEN1PSEN2
SCHEMBL12184418 0.74 SMN1; SMN2 (0.49) SMN1; SMN2
SCHEMBL13412496 0.74 NUDT1 (0.35) SMYD3SMN1; SMN2TSHRNNMTSIRT6
SCHEMBL21229089 0.74 ALDH1A1 (0.44) LOXL2LOXSMN1; SMN2
SCHEMBL5875703 0.74 HDAC1 (0.44) SMYD3SMN1; SMN2PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006504796-A 2006-02-09 JP claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP claimed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 US claimed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 WO claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP disclosed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 US disclosed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders APP, PARK7, IAPP LOXL2 4381/4885LOX 3272/4885SMYD3 4610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.